Join Growin Stock Community!

Xtant medical holdings, inc.XTNT.US Overview

US StockHealthcare
(No presentation for XTNT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

XTNT AI Insights

XTNT Overall Performance

XTNT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

XTNT Recent Performance

-2.79%

Xtant medical holdings, inc.

0.05%

Avg of Sector

-0.31%

S&P500

XTNT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

XTNT Key Information

XTNT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

XTNT Profile

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.

Price of XTNT

XTNT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

XTNT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.01
PE Ratio (TTM)
57.03
Forward PE
-
PS Ratio (TTM)
0.60
PB Ratio
1.58
Price-to-FCF
14.59
METRIC
VALUE
vs. INDUSTRY
Gross Margin
62.02%
Net Margin
1.32%
Revenue Growth (YoY)
16.88%
Profit Growth (YoY)
19.06%
3-Year Revenue Growth
31.99%
3-Year Profit Growth
40.70%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.01
PE Ratio (TTM)
57.03
Forward PE
-
PS Ratio (TTM)
0.60
PB Ratio
1.58
Price-to-FCF
14.59
Gross Margin
62.02%
Net Margin
1.32%
Revenue Growth (YoY)
16.88%
Profit Growth (YoY)
19.06%
3-Year Revenue Growth
31.99%
3-Year Profit Growth
40.70%

  • When is XTNT's latest earnings report released?

    The most recent financial report for Xtant medical holdings, inc. (XTNT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating XTNT's short-term business performance and financial health. For the latest updates on XTNT's earnings releases, visit this page regularly.

  • Where does XTNT fall in the P/E River chart?

    According to historical valuation range analysis, Xtant medical holdings, inc. (XTNT)'s current price-to-earnings (P/E) ratio is 60.85, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of XTNT?

    According to the latest financial report, Xtant medical holdings, inc. (XTNT) reported an Operating Profit of 2.54M with an Operating Margin of 7.64% this period, representing a growth of 167.28% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is XTNT's revenue growth?

    In the latest financial report, Xtant medical holdings, inc. (XTNT) announced revenue of 33.26M, with a Year-Over-Year growth rate of 19.04%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does XTNT have?

    As of the end of the reporting period, Xtant medical holdings, inc. (XTNT) had total debt of 32.49M, with a debt ratio of 0.31. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does XTNT have?

    At the end of the period, Xtant medical holdings, inc. (XTNT) held Total Cash and Cash Equivalents of 10.64M, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does XTNT go with three margins increasing?

    In the latest report, Xtant medical holdings, inc. (XTNT) achieved the “three margins increasing” benchmark, with a gross margin of 66.1%%, operating margin of 7.64%%, and net margin of 3.9%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess XTNT's profit trajectory and future growth potential.

  • Is XTNT's EPS continuing to grow?

    According to the past four quarterly reports, Xtant medical holdings, inc. (XTNT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of XTNT?

    Xtant medical holdings, inc. (XTNT)'s Free Cash Flow (FCF) for the period is 4.29M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 215.13% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.